{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["15(1)"],"submitter":["Park W"],"pubmed_abstract":["<h4>Objectives</h4>The aim of this study was to compare the long-term oncologic outcomes of sentinel lymph node biopsy (SLNB) versus elective neck dissection (END) in clinically node-negative (cN0) tongue cancer.<h4>Methods</h4>This was a retrospective cohort study of patients with cN0 tongue cancer from a single institution, including 91 patients in the SLNB group and 120 patients in the END group.<h4>Results</h4>The overall recurrence rate showed no significant difference between the two groups. The regional control rate was also comparable between the two groups (P=0.490). The 5-year recurrence-free survival (RFS) was slightly better in the SLNB group than in the END group (P=0.427). The 5-year overall survival (OS) rate was 89.9% in the SLNB group versus 91.9% in the END group (P=0.737"],"journal":["Clinical and experimental otorhinolaryngology"],"pagination":["107-114"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8901953"],"repository":["biostudies-literature"],"pubmed_title":["Sentinel Lymph Node Biopsy Versus Elective Neck Dissection: Long-Term Oncologic Outcomes in Clinically Node-Negative Tongue Cancer."],"pmcid":["PMC8901953"],"pubmed_authors":["Park W","Baek CH","Jin H","Heo Y","Jeong HS","Son YI","Chung MK"],"additional_accession":[]},"is_claimable":false,"name":"Sentinel Lymph Node Biopsy Versus Elective Neck Dissection: Long-Term Oncologic Outcomes in Clinically Node-Negative Tongue Cancer.","description":"<h4>Objectives</h4>The aim of this study was to compare the long-term oncologic outcomes of sentinel lymph node biopsy (SLNB) versus elective neck dissection (END) in clinically node-negative (cN0) tongue cancer.<h4>Methods</h4>This was a retrospective cohort study of patients with cN0 tongue cancer from a single institution, including 91 patients in the SLNB group and 120 patients in the END group.<h4>Results</h4>The overall recurrence rate showed no significant difference between the two groups. The regional control rate was also comparable between the two groups (P=0.490). The 5-year recurrence-free survival (RFS) was slightly better in the SLNB group than in the END group (P=0.427). The 5-year overall survival (OS) rate was 89.9% in the SLNB group versus 91.9% in the END group (P=0.737","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Feb","modification":"2025-04-04T08:53:19.214Z","creation":"2025-04-04T08:53:19.214Z"},"accession":"S-EPMC8901953","cross_references":{"pubmed":["33781056"],"doi":["10.21053/ceo.2020.02411"]}}